Internal Medicine Alert – November 15, 2003
November 15, 2003
View Issues
-
Keeping Abreast
Exercise reduces the risk of breast cancer after menopause. Although the exercise need not be strenuous, longer duration of exercise confers greater benefit. -
System Breakdown
Most postmenopausal women who suffer a fracture do not receive treatment for osteoporosis. -
Treatment of CAP with Levofloxacin
Treatment of CAP with 750 mg of levofloxacin daily for 5 days was as effective as a 10-day course of 500 mg daily. -
Pharmacology Update: Memantine Hydrochloride Tablets (Namenda)
The FDA has approved the first drug for the treatment of moderate-to-severe Alzheimers disease. Memantine, a noncompetitive inhibitor of the N-methyl-D-aspartate receptor, has been available outside of the United States since 1982. -
Clinical Briefs
Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis; Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis; Exercise Testing to Predict Cardiovascular and All-Cause Death in Women -
ECG Review: A Subtle Reality Rhythm?
The 12-lead ECG and accompanying lead II rhythm strip in the Figure were obtained from a 74-year-old man with sever pulmonary disease. The computer interpreted this tracing as showing normal sinus rhythm. Do you agree? -
Pharmacology Watch: Generic Paxil Scheduled to Hit Market this Fall
A generic form of paroxetine (PaxilGlaxoSmithKline) will soon be on the market. The drug marks the second SSRI antidepressant to go generic after fluoxetine (Prozac) last year.